Search Results
Apr 01, 2026, 23:59 ET 再鼎醫藥宣佈達成全球臨床研究合作及供應協議，以評估創新性DLL3抗體藥物偶聯物Zocilurtatug Pelitecan與雙特異性T細胞銜接器的聯合治療
References:[1] J Thorac Oncol. 2023 Jan;18(1):31-46; Lung Cancer Foundation of America. [2]
More news about: 再鼎醫藥
Apr 01, 2026, 12:37 ET NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
Mammography Workflows to Promote Lung Cancer Screening: A Feasibility Study," "A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs)," and "Increasing Equitable Adherence to Annual Lung Cancer Screening and Diagnostic
More news about: National Comprehensive Cancer Network
Apr 01, 2026, 09:00 ET IMMP Investor Alert: Immutep Ltd. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Trial Futility: Levi & Korsinsky
that an Independent Data Monitoring Committee (IDMC) recommended halting the Phase III TACTI-004 trial of eftilagimod alfa in first-line non-small-cell lung cancer because an interim futility analysis showed the drug was unlikely to meet its efficacy endpoints. If you suffered a loss on your Immutep investment,
More news about: Levi & Korsinsky, LLP
Apr 01, 2026, 08:50 ET Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Apr 01, 2026, 08:06 ET NCCN 2026 Annual Conference Prepares Cancer Care Providers Worldwide for Healing the Whole Patient
Mammography Workflows to Promote Lung Cancer Screening: A Feasibility Study," "A Phase I Study of Safety and Immunogenicity of Survivin Long Peptide Vaccine (SurVaxM) in Patients with Metastatic Neuroendocrine Tumors (NETs)," and "Increasing Equitable Adherence to Annual Lung Cancer Screening and Diagnostic
More news about: National Comprehensive Cancer Network
Mar 31, 2026, 18:00 ET Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect
74.1% (n=58)Lung86.7% (n=15)
More news about: Caris Life Sciences
Mar 31, 2026, 16:05 ET VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update
goal."In 2025 we not only received our first order for the Nu.Q® Cancer assays for clinical certification ahead of routine clinical use in lung cancer, but we also announced the inclusion of our Nu.Q® NETs assay in a real-world interventional evaluation of early detection of sepsis,
More news about: VolitionRx Limited
Mar 31, 2026, 08:28 ET NYU Langone Transplant Institute Celebrates 10 Years of Saving Lives
lung transplant programs are ranked No. 1 for quality in New York State, according to the federal
More news about: NYU Langone Health
Mar 31, 2026, 08:13 ET 3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone
spectrum of high-incidence tumors including squamous/non-squamous non-small cell lung cancer, metastatic colorectal cancer, extensive-stage small cell lung cancer, gastroesophageal junction cancer, transformed small cell lung cancer, locally advanced/metastatic hepatocellular carcinoma, locally advanced/metastatic
More news about: 3SBio Inc.
Mar 31, 2026, 08:05 ET Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
that over 229,000 adults in the U.S. will be diagnosed with lung cancer in 2026. Lung cancer is the leading cause of cancer death in the U.S., with non-small cell lung cancer (NSCLC) being the most common type accounting for 77% of all lung cancer diagnoses.1 RET fusions are implicated
More news about: Rigel Pharmaceuticals, Inc.
Mar 31, 2026, 05:40 ET Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026
the HARMONi-2 study at the 2026 European Lung Cancer Congress (ELCC). The study evaluated ivonescimab, the company's first-in-class PD-1/VEGF bispecific antibody, versus pembrolizumab as a first-line treatment for patients with PD-L1–positive non-small cell lung cancer (NSCLC). In the primary analyses
More news about: Akeso, Inc.
Mar 31, 2026, 03:16 ET Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program
CS014 showed favorable safety and tolerability profile in Phase I, development focus for Phase II is pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor
More news about: Cereno Scientific
Mar 31, 2026, 03:12 ET Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program
CS014 showed favorable safety and tolerability profile in Phase I, development focus for Phase II is pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor
More news about: Cereno Scientific
Mar 30, 2026, 09:05 ET Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Mar 30, 2026, 09:00 ET Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." In addition,
More news about: THE ROSEN LAW FIRM, P. A.
Mar 30, 2026, 08:20 ET 4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union
quantitative, insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease.These insights help respiratory physicians, radiologists and hospital teams quantify regional lung function, support diagnosis and disease monitoring, and inform treatment and
More news about: 4DMedical
Mar 30, 2026, 06:00 ET IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma
poly(ADP-ribose) glycohydrolase (PARG) inhibitor. The Phase 1 combination study will be evaluated in DLL3 upregulated solid tumor indications, including small cell lung cancer (SCLC), neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and melanoma.
More news about: IDEAYA Biosciences, Inc.
Mar 30, 2026, 02:20 ET 4DMedical receives CE Mark for CT:VQ™, enabling commercial launch across the European Union
quantitative, insights from routine clinical imaging to help clinicians assess lung function and cardiopulmonary disease.These insights help respiratory physicians, radiologists and hospital teams quantify regional lung function, support diagnosis and disease monitoring, and inform treatment and
More news about: 4DMedical
Mar 27, 2026, 16:45 ET Allergy & Asthma Network and Blue Marble Health Advance Digital Health Innovation with Evidence-Based Platform for Asthma Self-Management
award number R44HL137502 for the development of tools and platforms to improve the dissemination and implementation of evidence-based interventions for lung diseases and disorders. The content of the manuscript is solely the responsibility of the authors and does not necessarily represent the official views
More news about: Allergy & Asthma Network
Mar 27, 2026, 10:44 ET Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting
approved for use in RA patients.MalignancyMalignancies have occurred in patients treated with LEQSELVI. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients.Major Adverse Cardiovascular EventsHigher rate of MACE (defined
More news about: Sun Pharma
Mar 27, 2026, 10:00 ET AbbVie to Highlight New Clinical and Real-World Evidence Advancing Standards of Care in Immune-Mediated Skin Diseases at the 2026 AAD Annual Meeting
Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in
More news about: AbbVie
Mar 27, 2026, 08:39 ET Dizal's ZEGFROVY® (Sunvozertinib) Shows Profound Antitumor Activity as First-Line Treatment in Advanced NSCLC Patients with PACC or Other Uncommon Mutations at ELCC 2026
first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) P-Loop and αC-helix compressing (PACC) or other uncommon mutations. The data were presented at the 2026 European Lung Cancer Congress (ELCC), held in Copenhagen, Denmark from
More news about: Dizal
Mar 26, 2026, 23:54 ET Akeso Reports Full-Year 2025 Financial Results
nsq-NSCLC following third-generation EGFR-TKI failure. As the only commercialized PD-1/VEGF bispecific globally, ivonescimab has secured two approved lung cancer indications in China (both NRDL-listed) with another sNDA under review for the first-line treatment of advanced
More news about: Akeso, Inc.
Mar 26, 2026, 16:05 ET Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency
India.About ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed
More news about: Nuvation Bio Inc.; Eisai Co., Ltd
Mar 26, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1st line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." According
More news about: Pomerantz LLP